Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels

Medicine & Life Sciences

• Insulin-Like Growth Factor Binding Proteins 100%
• Insulin-Like Growth Factor II 95%
• Somatomedins 81%
• Random Allocation 74%
• Insulin-Like Growth Factor Binding Protein 3 71%
• Prostatic Neoplasms 60%
• Insulin-Like Growth Factor I 38%
• Single Nucleotide Polymorphism 31%
• Genetic Pleiotropy 30%
• Insulin-Like Growth Factor Binding Protein 2 27%
• Biomarkers 24%
• Peptides 24%
• Genome-Wide Association Study 19%
• Genes 15%
• Alleles 13%
• Mortality 9%